| Title: |
Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy. |
| Authors: |
Lordello, Leonardo1 (AUTHOR) leomelo@gmail.com, Nuan-Aliman, Stéphanie1 (AUTHOR) stephanie.nuan@gmail.com, Kielbassa-Elkadi, Karoline1 (AUTHOR) karoline.elkadi@gmail.com, Montagne, Aurélie1 (AUTHOR) aurelie.montagne@outlook.fr, Kotta, Konstantina1 (AUTHOR) kn.kotta@gmail.com, Martins, Isabelle2,3 (AUTHOR) isabellemart@gmail.com, Pinto Jurado, Eva1 (AUTHOR) pintoj.eva@gmail.com, Caradeuc, Cédric4 (AUTHOR) cedric.caradeuc@u-paris.fr, Lehmann-Che, Jacqueline5,6 (AUTHOR) jacqueline.lehmann-che@aphp.fr, Martínez-Climent, José Ángel7 (AUTHOR) jamcliment@unav.es, Meignin, Véronique1,8 (AUTHOR) veronique.meignin@aphp.fr, Giraud, Nicolas4 (AUTHOR) nicolas.giraud@u-paris.fr, Kroemer, Guido2,3,9 (AUTHOR) kroemer@orange.fr, Bertho, Gildas4 (AUTHOR) gildas.bertho@u-paris.fr, Thieblemont, Catherine1,10 (AUTHOR) catherine.thieblemont@aphp.fr, Baud, Véronique1 (AUTHOR) veronique.baud@inserm.fr |
| Source: |
Cancers. Feb2025, Vol. 17 Issue 3, p394. 19p. |
| Subject Terms: |
*THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of antimetabolites, *LIPID metabolism, *METFORMIN, *CANCER relapse, *RESEARCH funding, *NUCLEAR magnetic resonance spectroscopy, *GLYCOLYSIS, *ANTINEOPLASTIC agents, *APOPTOSIS, *CANCER patients, *ASPARAGINASE, *METABOLISM, *CELL survival, *B cell lymphoma, *TRICARBOXYLIC acids |
| Abstract: |
Simple Summary: Diffuse large B-cell lymphoma (DLBCL) is a very common and aggressive form of blood cancer. Despite therapeutic advances, ~40% of DLBCL patients will die. Metabolic reprogramming is a characteristic of cancer cells and a new potential therapeutic target. Our research focuses on developing strategies by targeting metabolic vulnerabilities to improve clinical outcomes for DLBCL patients with therapeutic impasses. Here, we report that combining two antimetabolic drugs, namely metformin and L-asparaginase, induced massive DLBCL cell killing compared to each drug alone. Further, we deciphered how this novel drug combination impacts critical metabolic and oncogenic pathways. Finally, we demonstrated the clinical benefit of this optimized antimetabolic drug treatment for DLBCL patients. Altogether, our data provide a framework for the use of an optimized combination of antimetabolic drugs to overcome resistance in DLBCL patients. Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, characterized by aggressive and heterogeneous tumors originating from B-cells. Especially in patients with relapsed or refractory (R/R) disease, DLBCL remains a challenging cancer to treat. Metabolic reprogramming is a hallmark of malignant cells. Our research focuses on developing strategies to enhance clinical outcomes for R/R DLBCL patients by targeting metabolic vulnerabilities. Methods: We investigated the effects of combining metformin and L-asparaginase, two FDA-approved antimetabolic drugs, on DLBCL cell metabolism and survival. Nuclear magnetic resonance (NMR) spectroscopy was employed to assess metabolic disturbances induced by the drug combination. The impact on lipid metabolism, glycolysis, glutaminolysis, the tricarboxylic acid (TCA) cycle, and antioxidant responses was examined. Induction of apoptosis was evaluated by FACS analysis. Results: The combination of metformin and L-asparaginase strongly sensitized DLBCL cells to apoptosis, independently of their oxidative phosphorylation (OxPhos) or BCR/glycolytic status. NMR spectroscopy revealed that this combination induces broader metabolic disturbances than either drug alone. It disrupts lipid metabolism by altering levels of phospholipids, cholesterol, and fatty acids. Additionally, it counteracts the pro-glycolytic effect of metformin, decreases glycolysis, and reduces glutaminolysis. It also affects the TCA cycle and antioxidant responses, critical for cellular energy production and redox balance. Furthermore, this combination interferes with two key cancer survival pathways, mTORC1 and MAPK signaling. Importantly, proof of principle for its beneficial effect was demonstrated in DLBCL patients. Conclusions: Combining metformin and L-asparaginase affects DLBCL cell survival by targeting multiple metabolic pathways and may represent a novel therapeutic approach for R/R DLBCL patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
